#835 – The Industry Wire

September 18, 2026 Brian Casey 0 min read
  1. RFK, Jr. shifts USPSTF panel’s focus away from primary care. 
  2. Pharma companies aren’t completing postmarket drug studies. 
  3. ACGME suggests eliminating some work protections for residents. 
  4. Semaglutide is good for even frail heart disease patients. 
  5. Low patient volume drags down hospital operating margins. 
  6. Elective surgeries drop as patients lose healthcare coverage.
  7. CVS Aetna streamlines prior auths for cancer. 
  8. J&J sells closure device firm it bought just three years ago. 
  9. How will the Federal Reserve’s rate hike affect biotech stocks?
  10. Report: Agentic AI boom is outpacing governance efforts.
Get every issue of The Imaging Wire, delivered right to your inbox.

You might also like

Artificial Intelligence October 15, 2026

Big Prostate AI Study Supports Screening Role October 15, 2026

A new study testing AI performance in analyzing prostate MRI exams could lay the groundwork for the technology’s broader role in prostate cancer screening.

Artificial Intelligence October 12, 2026

Blackford Finds Buyer with Sopris Acquisition October 12, 2026

Private equity firm Sopris Capital acquired AI platform company Blackford Analysis, resolving a year-long question over Blackford’s fate.

Imaging Policy October 8, 2026

How Common Are Imaging Deserts? October 8, 2026

How common are imaging deserts in radiology? The problem may not be as bad as you think.